Table 2.
Activity of Distinct Antimicrobial Agents Tested Against 13 752 Acinetobacter calcoacetius–A. baumannii Complex Isolates by Geographic Region (SENTRY Program, 1997–2016)
| CLSIa | EUCASTa | ||||||
|---|---|---|---|---|---|---|---|
| Geographic Region (No. Tested) Antimicrobial Agent | MIC50, mg/L | MIC90, mg/L | %S | %R | %S | %R | |
| Asia-Pacific (2327)b | |||||||
| Amikacin | >32 | >32 | 42.9 | 54.8 | 41.2 | 57.1 | |
| Ampicillin-sulbactam (1799)c | >16 | >16 | 26.9 | 67.6 | d | d | |
| Cefepime | >16 | >16 | 32.9 | 60.3 | d | d | |
| Ceftazidime | >16 | >16 | 33.3 | 64.2 | d | d | |
| Colistin (1665)c | ≤0.5 | 1 | 97.5 | 2.5 | 97.5 | 2.5 | |
| Gentamicin | >8 | >8 | 34.4 | 64.0 | 34.4 | 65.6 | |
| Imipenem | >8 | >8 | 42.0 | 55.7 | 42.0 | 54.0 | |
| Levofloxacin | >4 | >4 | 34.0 | 55.2 | 32.5 | 67.1 | |
| Meropenem | >8 | >8 | 42.0 | 56.2 | 42.0 | 55.5 | |
| Minocycline (1589)c | 4 | 8 | 80.3 | 4.7 | d | d | |
| Piperacillin-tazobactam | >64 | >64 | 29.6 | 64.5 | d | d | |
| Tigecycline (1692)c | 1 | 2 | d | d | d | d | |
| Tobramycin | >8 | >8 | 42.3 | 56.4 | 42.3 | 57.7 | |
| Trimethoprim-sulfamethoxazole | >4 | >4 | 38.4 | 61.4 | 38.4 | e | |
| Europe (4531)f | |||||||
| Amikacin | >32 | >32 | 32.1 | 64.7 | 29.9 | 67.9 | |
| Ampicillin-sulbactam (3754)c | >16 | >16 | 25.2 | 65.1 | d | d | |
| Cefepime | >16 | >16 | 23.9 | 63.8 | d | d | |
| Ceftazidime | >16 | >16 | 19.8 | 74.0 | d | d | |
| Colistin (3275)c | ≤0.5 | 2 | 93.9 | 6.1 | 93.9 | 6.1 | |
| Gentamicin | >8 | >8 | 26.2 | 69.5 | 26.2 | 73.8 | |
| Imipenem | >8 | >8 | 39.4 | 58.1 | 39.4 | 55.5 | |
| Levofloxacin | >4 | >4 | 21.1 | 68.5 | 18.1 | 80.7 | |
| Meropenem | >8 | >8 | 35.6 | 60.5 | 35.6 | 53.9 | |
| Minocycline (2995)c | 2 | >8 | 70.1 | 17.7 | d | d | |
| Piperacillin-tazobactam | >64 | >64 | 18.8 | 74.9 | d | d | |
| Tigecycline (3600)c | 1 | 2 | d | d | d | d | |
| Tobramycin | 8 | >8 | 46.0 | 49.9 | 46.0 | 54.0 | |
| Trimethoprim-sulfamethoxazole | >4 | >4 | 35.2 | 64.8 | 35.2 | e | |
| Latin America (3367)g | |||||||
| Amikacin | >32 | >32 | 26.4 | 67.5 | 22.7 | 73.6 | |
| Ampicillin-sulbactam (2643)c | >16 | >16 | 21.6 | 61.9 | d | d | |
| Cefepime | >16 | >16 | 18.4 | 69.4 | d | d | |
| Ceftazidime | >16 | >16 | 14.7 | 80.2 | d | d | |
| Colistin (2246)c | ≤0.5 | 2 | 98.1 | 1.9 | 98.1 | 1.9 | |
| Gentamicin | >8 | >8 | 28.0 | 62.4 | 28.0 | 72.0 | |
| Imipenem | >8 | >8 | 44.7 | 53.1 | 44.7 | 51.6 | |
| Levofloxacin | >4 | >4 | 15.7 | 76.3 | 14.6 | 84.7 | |
| Meropenem | >8 | >8 | 41.0 | 54.6 | 41.0 | 51.3 | |
| Minocycline (2128)c | ≤1 | 4 | 91.1 | 4.9 | d | d | |
| Piperacillin-tazobactam | >64 | >64 | 12.8 | 78.0 | d | d | |
| Tigecycline (2554)c | 1 | 2 | d | d | d | d | |
| Tobramycin | >8 | >8 | 44.6 | 51.9 | 44.6 | 55.4 | |
| Trimethoprim-sulfamethoxazole | >4 | >4 | 24.7 | 75.3 | 24.7 | e | |
| North America (3527)h | |||||||
| Amikacin | ≤4 | >32 | 72.3 | 22.5 | 67.5 | 27.7 | |
| Ampicillin-sulbactam (2813)c | 8 | >16 | 54.7 | 31.9 | d | d | |
| Cefepime | 16 | >16 | 46.6 | 41.5 | d | d | |
| Ceftazidime | 16 | >16 | 48.4 | 44.9 | d | d | |
| Colistin (2461)c | ≤0.5 | 2 | 95.4 | 4.6 | 95.4 | 4.6 | |
| Gentamicin | 4 | >8 | 54.0 | 41.6 | 54.0 | 46.0 | |
| Imipenem | ≤0.5 | >8 | 63.9 | 32.0 | 63.9 | 27.0 | |
| Levofloxacin | 4 | >4 | 48.4 | 48.3 | 46.0 | 52.7 | |
| Meropenem | 1 | >8 | 59.7 | 36.5 | 59.7 | 32.6 | |
| Minocycline (2205)c | ≤1 | 8 | 81.6 | 8.2 | d | d | |
| Piperacillin-tazobactam | 32 | >64 | 44.8 | 43.5 | d | d | |
| Tigecycline (2708)c | 0.5 | 2 | d | d | d | d | |
| Tobramycin | 1 | >8 | 65.9 | 29.9 | 65.9 | 34.1 | |
| Trimethoprim-sulfamethoxazole | 1 | >4 | 53.3 | 46.7 | 53.3 | e | |
Abbreviations: CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing; MIC, minimum inhibitory concentration; R, resistant; S, susceptible.
bOrganisms include A. baumannii (1), A. calcoacetius–A. baumannii complex (2317), A. nosocomialis (4), A. pittii (5).
cLess than 90% of isolates tested against these antimicrobials; number of isolates tested is cited in parentheses.
eDilution range did not extend high enough to determine between intermediate and R, so only the S percentage is displayed.
fOrganisms include A. baumannii (4), A. calcoacetius–A. baumannii complex (4448), A. nosocomialis (5), A. pittii (74).
gOrganisms include A. baumannii (1), A. calcoacetius–A. baumannii complex (3353), A. nosocomialis (5), A. pittii (8).
hOrganisms include A. baumannii (2), A. calcoacetius–A. baumannii complex (3436), A. nosocomialis (26), A. pittii (63).